Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	B:C0001186
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	O
and	O
Src	O
kinase	I:C0282625
inhibitors	O
for	O
antitumor	O
treatment	O
Overexpression	O
of	O
EGFR	O
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	O
and	O
poor	O
prognosis	I:C0278252
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	B:C0034802
and	O
Src	O
kinase	I:C0282625
inhibitors	O
for	O
antitumor	O
treatment	O
Overexpression	O
of	O
EGFR	O
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	O
and	O
poor	O
prognosis	I:C0278252
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	O
and	O
Src	B:C0282625
kinase	I:C0282625
inhibitors	O
for	O
antitumor	O
treatment	O
Overexpression	O
of	O
EGFR	O
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	O
and	O
poor	O
prognosis	I:C0278252
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	O
and	O
Src	O
kinase	I:C0282625
inhibitors	B:C3537035
for	O
antitumor	O
treatment	O
Overexpression	O
of	O
EGFR	O
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	O
and	O
poor	O
prognosis	I:C0278252
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	O
and	O
Src	O
kinase	I:C0282625
inhibitors	O
for	O
antitumor	O
treatment	B:C0087111
Overexpression	O
of	O
EGFR	O
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	O
and	O
poor	O
prognosis	I:C0278252
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	O
and	O
Src	O
kinase	I:C0282625
inhibitors	O
for	O
antitumor	O
treatment	O
Overexpression	B:C1514559
of	O
EGFR	O
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	O
and	O
poor	O
prognosis	I:C0278252
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	O
and	O
Src	O
kinase	I:C0282625
inhibitors	O
for	O
antitumor	O
treatment	O
Overexpression	O
of	O
EGFR	B:C0034802
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	O
and	O
poor	O
prognosis	I:C0278252
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	O
and	O
Src	O
kinase	I:C0282625
inhibitors	O
for	O
antitumor	O
treatment	O
Overexpression	O
of	O
EGFR	O
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	B:C0012634
and	O
poor	O
prognosis	I:C0278252
.	O

Design	O
,	O
synthesis	O
and	O
evaluation	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
dual	O
-	O
target	O
EGFR	O
and	O
Src	O
kinase	I:C0282625
inhibitors	O
for	O
antitumor	O
treatment	O
Overexpression	O
of	O
EGFR	O
is	O
often	O
associated	O
with	O
advanced	O
stage	O
disease	O
and	O
poor	B:C0278252
prognosis	I:C0278252
.	O

In	O
certain	O
cancers	B:C0007097
,	O
Src	O
works	O
synergistically	O
with	O
EGFR	O
to	O
promote	O
proliferation	O
,	O
survival	O
,	O
invasion	O
and	O
metastasis	O
.	O

In	O
certain	O
cancers	O
,	O
Src	B:C0282625
works	O
synergistically	O
with	O
EGFR	O
to	O
promote	O
proliferation	O
,	O
survival	O
,	O
invasion	O
and	O
metastasis	O
.	O

In	O
certain	O
cancers	O
,	O
Src	O
works	O
synergistically	O
with	O
EGFR	B:C0034802
to	O
promote	O
proliferation	O
,	O
survival	O
,	O
invasion	O
and	O
metastasis	O
.	O

In	O
certain	O
cancers	O
,	O
Src	O
works	O
synergistically	O
with	O
EGFR	O
to	O
promote	O
proliferation	B:C0596290
,	O
survival	O
,	O
invasion	O
and	O
metastasis	O
.	O

In	O
certain	O
cancers	O
,	O
Src	O
works	O
synergistically	O
with	O
EGFR	O
to	O
promote	O
proliferation	O
,	O
survival	B:C0007620
,	O
invasion	O
and	O
metastasis	O
.	O

In	O
certain	O
cancers	O
,	O
Src	O
works	O
synergistically	O
with	O
EGFR	O
to	O
promote	O
proliferation	O
,	O
survival	O
,	O
invasion	B:C2699153
and	O
metastasis	O
.	O

In	O
certain	O
cancers	O
,	O
Src	O
works	O
synergistically	O
with	O
EGFR	O
to	O
promote	O
proliferation	O
,	O
survival	O
,	O
invasion	O
and	O
metastasis	B:C4255448
.	O

Development	O
of	O
dual	O
-	O
target	O
drugs	B:C0013227
against	O
EGFR	O
and	O
Src	O
is	O
of	O
therapeutic	O
advantage	O
against	O
these	O
cancers	O
.	O

Development	O
of	O
dual	O
-	O
target	O
drugs	O
against	O
EGFR	B:C0034802
and	O
Src	O
is	O
of	O
therapeutic	O
advantage	O
against	O
these	O
cancers	O
.	O

Development	O
of	O
dual	O
-	O
target	O
drugs	O
against	O
EGFR	O
and	O
Src	B:C0282625
is	O
of	O
therapeutic	O
advantage	O
against	O
these	O
cancers	O
.	O

Development	O
of	O
dual	O
-	O
target	O
drugs	O
against	O
EGFR	O
and	O
Src	O
is	O
of	O
therapeutic	O
advantage	O
against	O
these	O
cancers	B:C0007097
.	O

Based	O
on	O
molecular	B:C3494274
docking	I:C3494274
and	O
our	O
previous	O
studies	O
,	O
we	O
rationally	O
designed	O
a	O
new	O
series	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
potent	O
EGFR	O
and	O
Src	O
dual	O
inhibitors	O
.	O

Based	O
on	O
molecular	O
docking	I:C3494274
and	O
our	O
previous	O
studies	B:C2603343
,	O
we	O
rationally	O
designed	O
a	O
new	O
series	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
potent	O
EGFR	O
and	O
Src	O
dual	O
inhibitors	O
.	O

Based	O
on	O
molecular	O
docking	I:C3494274
and	O
our	O
previous	O
studies	O
,	O
we	O
rationally	O
designed	O
a	O
new	O
series	O
of	O
azaacridine	B:C0001186
derivatives	I:C0001186
as	O
potent	O
EGFR	O
and	O
Src	O
dual	O
inhibitors	O
.	O

Based	O
on	O
molecular	O
docking	I:C3494274
and	O
our	O
previous	O
studies	O
,	O
we	O
rationally	O
designed	O
a	O
new	O
series	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
potent	O
EGFR	B:C0034802
and	O
Src	O
dual	O
inhibitors	O
.	O

Based	O
on	O
molecular	O
docking	I:C3494274
and	O
our	O
previous	O
studies	O
,	O
we	O
rationally	O
designed	O
a	O
new	O
series	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
potent	O
EGFR	O
and	O
Src	B:C0282625
dual	O
inhibitors	O
.	O

Based	O
on	O
molecular	O
docking	I:C3494274
and	O
our	O
previous	O
studies	O
,	O
we	O
rationally	O
designed	O
a	O
new	O
series	O
of	O
azaacridine	O
derivatives	I:C0001186
as	O
potent	O
EGFR	O
and	O
Src	O
dual	O
inhibitors	B:C3537035
.	O

Most	O
of	O
the	O
synthesized	O
azaacridines	B:C0001186
displayed	O
good	O
antiproliferative	O
activity	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
.	O

Most	O
of	O
the	O
synthesized	O
azaacridines	O
displayed	O
good	O
antiproliferative	O
activity	O
against	O
K562	B:C0600432
and	O
A549	O
cells	I:C4277577
.	O

Most	O
of	O
the	O
synthesized	O
azaacridines	O
displayed	O
good	O
antiproliferative	O
activity	O
against	O
K562	O
and	O
A549	B:C4277577
cells	I:C4277577
.	O

The	O
representative	O
compound	B:C1254351
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	B:C0600432
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	B:C4277577
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	B:C0034802
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	B:C0282625
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	B:C1254351
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	B:C1171362
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	B:C0034802
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	B:C0034802
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	B:C0282625
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	B:C0282625
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	B:C1254351
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	B:C1269955
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	B:C0334227
cells	I:C0334227
apoptosis	O
.	O

The	O
representative	O
compound	O
13	I:C1254351
b	I:C1254351
showed	O
nM	O
IC50	O
values	O
against	O
K562	O
and	O
A549	O
cells	I:C4277577
,	O
and	O
inhibited	O
EGFR	O
at	O
inhibition	O
rate	O
of	O
33.53	O
%	O
at	O
10	O
μM	O
and	O
Src	O
at	O
inhibition	O
rate	O
of	O
72.12	O
%	O
at	O
1	O
μM.	O
Furthermore	O
,	O
compound	O
13b	I:C1254351
could	O
inhibit	O
the	O
expression	O
of	O
EGFR	O
,	O
p-EGFR	O
,	O
Src	O
and	O
p-Src.	O
Moreover	O
,	O
13b	O
efficiently	O
inhibited	O
the	O
invasion	O
of	I:C1269955
tumor	I:C1269955
cells	I:C1269955
and	O
induced	O
cancer	O
cells	I:C0334227
apoptosis	B:C0162638
.	O

Our	O
study	B:C2603343
suggested	O
that	O
azaacridine	O
scaffold	O
can	O
be	O
developed	O
as	O
novel	O
multi-target	O
kinase	I:C3537035
inhibitors	I:C3537035
for	O
cancer	O
therapy	I:C0920425
.	O

Our	O
study	O
suggested	O
that	O
azaacridine	B:C0001186
scaffold	O
can	O
be	O
developed	O
as	O
novel	O
multi-target	O
kinase	I:C3537035
inhibitors	I:C3537035
for	O
cancer	O
therapy	I:C0920425
.	O

Our	O
study	O
suggested	O
that	O
azaacridine	O
scaffold	O
can	O
be	O
developed	O
as	O
novel	O
multi-target	B:C3537035
kinase	I:C3537035
inhibitors	I:C3537035
for	O
cancer	O
therapy	I:C0920425
.	O

Our	O
study	O
suggested	O
that	O
azaacridine	O
scaffold	O
can	O
be	O
developed	O
as	O
novel	O
multi-target	O
kinase	I:C3537035
inhibitors	I:C3537035
for	O
cancer	B:C0920425
therapy	I:C0920425
.	O

